Category: 89396-94-1

Cheng, Ivy; Sasegbon, Ayodele; Hamdy, Shaheen published the article 《Effects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta-analysis》. Keywords: neurogenic oropharyngeal dysphagia pharmacol agent meta analysis; drugs; dysphagia; meta-analysis; pharmacotherapy; systematic review; treatment.They researched the compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride( cas:89396-94-1 ).Recommanded Product: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride. Aromatic heterocyclic compounds can be divided into two categories: single heterocyclic and fused heterocyclic. In addition, there is a lot of other information about this compound (cas:89396-94-1) here.

This systematic review and meta-anal. aimed to evaluate the effects of pharmacol. agents for neurogenic oropharyngeal dysphagia based on evidence from randomized controlled trials (RCTs). Electronic databases were systematically searched between Jan. 1970 and March 2021. Two reviewers independently extracted and synthesized the data. The outcome measure was changed in (any) relevant clin. swallowing-related characteristics. Data from 2186 dysphagic patients were collected from 14 RCT studies across a range of pharmacotherapies. The pooled effect size of transient receptor potential (TRP) channel agonists was large compared to placebo interventions (SMD[95%CI] =1.27[0.74,1.80], p < 0.001; I2 = 79%). Data were limited for other pharmacol. agents and the overall pooled effect size of these agents was non-significant (SMD [95% CI] =0.25 [-0.24, 0.73]; p = 0.31; I2 = 85%). When analyzed sep., large effect sizes were observed with Nifedipine (SMD[95%CI] =1.13[0.09,2.18]; p = 0.03) and Metoclopramide (SMD[95%CI] =1.68[1.08,2.27]; p < 0.001). By contrast, the effects of angiotensin-converting enzyme (ACE) inhibitors (SMD[95%CI] = -0.67[-2.32,0.99]; p = 0.43; I2 = 61%), Physostigmine (SMD[95%CI] = -0.05[-1.03,0.93]; p = 0.92) and Glyceryl Trinitrate (GTN) (SMD [95% CI] = -0.01 [-0.11, 0.08]; p = 0.78) were non-significant. Within stroke patients, subgroup anal. showed that TRP channel agonists had a moderate pooled effect size (SMD[95%CI] =0.74[0.10,1.39]; p = 0.02; I2 = 82%) whereas the effects of other agents were non-significant (SMD[95%CI] =0.40[-0.04,0.84]; p = 0.07; I2 = 87%). Our results showed that TRP channel agonists, Nifedipine and Metoclopromide may be beneficial for neurogenic dysphagic patients. Large scale, multicenter clin. trials are warranted to fully explore their therapeutic effects on swallowing. There are many compounds similar to this compound(89396-94-1)Recommanded Product: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride. if you want to know more, you can check out my other articles. I hope it will help you，maybe you’ll find some useful information.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

Synthetic Route of C20H28ClN3O6. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, is researched, Molecular C20H28ClN3O6, CAS is 89396-94-1, about Estimation of Imidapril hydrochloride by UV – visible spectroscopic method in different solvents. Author is Prapulla, P.; Babu, B.; Maheshwari, T.; Paramesh, K.; Swathi, G.; Madhavi, K.; Hemamalini, K..

The objective of the project work was to developed and validated simple, accurate, rapid, precise, reproducible and cost effective spectrophotometric method for the quant. estimation of Imidapril HCl in different solvents like 0.1N HCl, Distilled water and 0.1N NaOH in bulk based on measurement of absorption at maximum wavelength and validated as per ICH guidelines. Imidapril hydrochloride is a angiotensin-converting enzyme (ACE) inhibitor with IC50 of 2.6 nM, used for the treatment of hypertension. Imidapril HCl showed absorption maximum (λmax) in different manner in different solvents like 0.1N Hydrochloric acid, Distilled Water and 0.1N Sodium Hydroxide Solution at 217 nm, 293 nm, and 236 nm resp. The drug exhibited maximum wavelength (nm) in distilled water, 293 nm when compared with other solvents due to the effect of solvent and chromophoric group. Thus the conclusion was made that the proposed UV Spectrophotometric method were found to be simple, rapid, accurate, precise, linear and more economical method has been developed for the quant. estimation of imidapril HCl in bulk. Hence, this method can be successfully and suitably acquired for routine quality control anal. of imidapril HC in bulk form.

There are many compounds similar to this compound(89396-94-1)Synthetic Route of C20H28ClN3O6. if you want to know more, you can check out my other articles. I hope it will help you，maybe you’ll find some useful information.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

Product Details of 89396-94-1. Aromatic heterocyclic compounds can also be classified according to the number of heteroatoms contained in the heterocycle: single heteroatom, two heteroatoms, three heteroatoms and four heteroatoms. Compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, is researched, Molecular C20H28ClN3O6, CAS is 89396-94-1, about Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Author is Sato, Atsuhisa; Suzuki, Yoshiyuki; Shibata, Hirotaka; Saruta, Takao.

There is increasing evidence of important cardiovascular effects of aldosterone via classical mineralocorticoid receptors in the heart. Aldosterone plus excess salt administration has been shown to produce both cardiac hypertrophy and cardiac fibrosis in rats. Various clin. studies have reported that aldosterone plays an important role in cardiac hypertrophy; however, the factors that control plasma aldosterone concentrations during angiotensin-converting enzyme (ACE) inhibitor treatment have still not been established. In the present study, we examined the relationship between plasma aldosterone concentrations and the degree of ACE inhibition in 25 essential hypertensive patients treated with an ACE inhibitor. Blood pressure decreased with treatment and plasma ACE activity, estimated in vitro (by a colorimetric method) and in vivo (by plasma angiotensin II/angiotensin I ratio) assay, was suppressed compared with that of hypertensive patients treated with medication other than ACE inhibitors. No relationship was found between the level of ACE inhibition and plasma aldosterone concentrations, which rose in parallel with the duration of ACE inhibitor treatment. The present study demonstrates that continuous ACE inhibitor therapy produces significant suppression of plasma ACE activity in essential hypertensive patients, but that no relationship exists between plasma aldosterone concentrations and levels of ACE inhibition. Plasma aldosterone concentrations tend to increase with the duration of ACE inhibitor treatment, although this increase did not reflect a reduced inhibition of ACE activity.

I hope my short article helps more people learn about this compound((S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride)Product Details of 89396-94-1. Apart from the compound(89396-94-1), you can read my other articles to know other related compounds.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

The chemical properties of alicyclic heterocycles are similar to those of the corresponding chain compounds. Compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, is researched, Molecular C20H28ClN3O6, CAS is 89396-94-1, about Studies on angiotensin converting enzyme inhibitors. V. The diastereoselective synthesis of 2-oxoimidazolidine derivatives, the main research direction is imidapril asym synthesis; enalapril diastereoselective synthesis; imidazolidinone derivative diastereoselective synthesis; angiotensin converting enzyme inhibitor imidapril.Application of 89396-94-1.

A diastereoselective synthesis of imidapril (I; R = H.HCl) (II), which is under clin. study as an antihypertensive drug based on its angiotensin converting enzyme (ACE)-inhibitory activity, was established. N-Alkylation of (2S)-2-amino-4-phenylbutyric acid Et ester with 3-((2R)-2-methane- or toluenesulfonyloxypropionyl)-2-oxoimidazolidine derivative III (R = Me, p-tolyl) diastereoselectively proceeded in an SN2 fashion to afford tert-Bu (4S)-3-[(2S)-2-[N-[(1S)-1-ethoxycarbonyl)-3-phenylpropyl]amino]propionyl]-1-methyl-2-oxoimidazolidine-4-carboxylate I (R = CMe3), a precursor of II. Alternatively benzyl (2S)-2-[N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]propionate IV, which is the key building block of I (R = CMe3), was synthesized by the same strategy. This procedure was also applied to the synthesis of enalapril.

Here is just a brief introduction to this compound(89396-94-1)Application of 89396-94-1, more information about the compound((S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride) is in the article, you can click the link below.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

The preparation of ester heterocycles mostly uses heteroatoms as nucleophilic sites, which are achieved by intramolecular substitution or addition reactions. Compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride( cas:89396-94-1 ) is researched.Quality Control of (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride.Maeda, Akira; Miyamoto, Tetsuo; Sato, Tomoki; Nakane, Toshiharu published the article 《Bioequivalence study of imidapril hydrochloride 2.5mg [NICHIIKO], imidapril hydrochloride 5mg [NICHIIKO] and imidapril hydrochloride 10mg [NICHIIKO] on healthy adults》 about this compound( cas:89396-94-1 ) in Igaku to Yakugaku. Keywords: imidapril hydrochloride tablet bioequivalence generic. Let’s learn more about this compound (cas:89396-94-1).

Here, the authors examined the bioequivalence of imidapril hydrochloride tablets on healthy adults. The bioequivalences of imidapril hydrochloride tablets were compared to tanatril tablets (reference products) by the parameters of AUC and Cmax. Since the confidence intervals of the differences between the means of the logarithmic AUC and Cmax of the test and reference products were within the acceptable range specified in the guideline , it was concluded that the test products were biol. equivalent to the reference products.

Here is just a brief introduction to this compound(89396-94-1)Quality Control of (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, more information about the compound((S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride) is in the article, you can click the link below.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

The chemical properties of alicyclic heterocycles are similar to those of the corresponding chain compounds. Compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, is researched, Molecular C20H28ClN3O6, CAS is 89396-94-1, about Analysis of Intra- and Intersubject Variability in Oral Drug Absorption in Human Bioequivalence Studies of 131 Generic Products, the main research direction is oral drug absorption variability human bioequivalence; BCS; CYP3A4; bioequivalence; intrasubject variability; solubility-limited absorption.Name: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride.

In this study, the data of 113 human bioequivalence (BE) studies of immediate release (IR) formulations of 74 active pharmaceutical ingredients (APIs) conducted at Sawai Pharmaceutical Co., Ltd., was analyzed to understand the factors affecting intra- and intersubject variabilities in oral drug absorption. The ANOVA CV (%) calculated from area under the time-concentration curve (AUC) in each BE study was used as an index of intrasubject variability (Vintra), and the relative standard deviation (%) in AUC was used as that of intersubject variability (Vinter). Although no significant correlation was observed between Vintra and Vinter of all drugs, Vintra of class 3 drugs was found to increase in association with a decrease in drug permeability (Peff). Since the absorption of class 3 drugs was rate-limited by the permeability, it was suggested that, for such drugs, the low Peff might be a risk factor to cause a large intrasubject variability. To consider the impact of poor water solubility on the variability in BE study, a parameter of Peff/Do (Do; dose number) was defined to discriminate the solubility-limited and dissolution-rate-limited absorption of class 2 drugs. It was found that the class 2 drugs with a solubility-limited absorption (Peff/Do < 0.149×10-4 cm/s) showed high intrasubject variability. Furthermore, as a reason for high intra- or intersubject variability in AUC for class 1 drugs, effects of drug metabolizing enzymes were investigated. It was demonstrated that intrasubject variability was high for drugs metabolized by CYP3A4 while intersubject variability was high for drugs metabolized by CYP2D6. For CYP3A4 substrate drugs, the Km value showed the significant relation with Vintra, indicating that the affinity to the enzyme can be a parameter to predict the risk of high intrasubject variability. In conclusion, by analyzing the in house data of human BE study, low permeability, solubility-limited absorption, and high affinity to CYP3A4 are identified as risk factors for high intrasubject variability in oral drug absorption. This information is of importance to design the human BE study for oral drug products containing APIs with a risk of large intrasubject variability in oral absorption. Compound(89396-94-1)Name: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride received a lot of attention, and I have introduced some compounds in other articles, similar to this compound((S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride), if you are interested, you can check out my other related articles.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

Name: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride. The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, is researched, Molecular C20H28ClN3O6, CAS is 89396-94-1, about Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. Author is Sato, A.; Saruta, T..

Continuous angiotensin-converting enzyme (ACE) inhibitor therapy does not necessarily produce significant decreases in plasma aldosterone levels (aldosterone escape). We examined the role of aldosterone escape in 75 essential hypertensive patients treated with an ACE inhibitor (enalapril maleate [34 patients], imidapril hydrochloride [24 patients] or trandolapril [17 patients]) for 40 wk. With treatment, blood pressure decreased and plasma renin activity increased, while plasma aldosterone concentrations did not change. Aldosterone escape was observed in 38 of the 75 patients and in 17 of 37 patients with left ventricular hypertrophy before treatment. Left ventricular mass index did not change in patients with aldosterone escape but decreased significantly in patients without aldosterone escape. The present study demonstrated a high incidence of aldosterone escape in patients with essential hypertension despite the use of ACE inhibitors. The results also suggest that aldosterone escape may reverse the beneficial effects of an ACE inhibitor on left ventricular hypertrophy.

Compounds in my other articles are similar to this one((S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride)Name: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, you can compare them to see their pros and cons in some ways,such as convenient, effective and so on.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic.Hosoya, Kazuyoshi; Ishimitsu, Toshihiko researched the compound: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride( cas:89396-94-1 ).Product Details of 89396-94-1.They published the article 《Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor》 about this compound( cas:89396-94-1 ) in Cardiovascular Drug Reviews. Keywords: review ACE inhibitor antihypertensive imidapril hypertension dysphagia CHF. We’ll tell you more about this compound (cas:89396-94-1).

A review. Imidapril hydrochloride (imidapril) is a long-acting, non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor, which has been used clin. in the treatment of hypertension, chronic congestive heart failure (CHF), acute myocardial infarction (AMI), and diabetic nephropathy. It has the unique advantage over other ACE inhibitors in causing a lower incidence of dry cough. After oral administration, imidapril is rapidly converted in the liver to its active metabolite imidaprilat. The plasma levels of imidaprilat gradually increase in proportion to the dose, and decline slowly. The time to reach the maximum plasma concentration (Tmax) is 2.0 h for imidapril and 9.3 h for imidaprilat. The elimination half-lives (t1/2) of imidapril and imidaprilat is 1.7 and 14.8 h, resp. Imidapril and its metabolites are excreted chiefly in the urine. As an ACE inhibitor, imidaprilat is as potent as enalaprilat, an active metabolite of enalapril, and about twice as potent as captopril. In patients with hypertension, blood pressure was still decreased at 24 h after imidapril administration. The antihypertensive effect of imidapril was dose-dependent. The maximal reduction of blood pressure and plasma ACE was achieved with imidapril, 10 mg once daily, and the addnl. effect was not prominent with higher doses. When administered to patients with AMI, imidapril improved left ventricular ejection fraction and reduced plasma brain natriuretic peptide (BNP) levels. In patients with mild-to-moderate CHF [New York Heart Association (NYHA) functional class II-III], imidapril increased exercise time and phys. working capacity and decreased plasma atrial natriuretic peptide (ANP) and BNP levels in a dose-related manner. In patients with diabetic nephropathy, imidapril decreased urinary albumin excretion. Interestingly, imidapril improved asymptomatic dysphagia in patients with a history of stroke. In the same patients it increased serum substance P levels, while the angiotensin II receptor antagonist losartan was ineffective. These studies indicate that imidapril is a versatile ACE inhibitor. In addition to its effectiveness in the treatment of hypertension, CHF, and AMI, imidapril has beneficial effects in the treatment of diabetic nephropathy and asymptomatic dysphagia. Good tissue penetration and inhibition of tissue ACE by imidapril contributes to its effectiveness in preventing cardiovascular complications of hypertension. The major advantages of imidapril are its activity in the treatment of various cardiovascular diseases and lower incidence of cough compared with some of the older ACE inhibitors.

In some applications, this compound(89396-94-1)Product Details of 89396-94-1 is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

In organic chemistry, atoms other than carbon and hydrogen are generally referred to as heteroatoms. The most common heteroatoms are nitrogen, oxygen and sulfur. Now I present to you an article called Bioequivalence study of imidapril hydrochloride Tab. 2.5mg [SAWAI], imidapril hydrochloride Tab. 5mg [SAWAI] and imidapril hydrochloride Tab. 10mg [SAWAI] on health adults, published in 2008-09-30, which mentions a compound: 89396-94-1, mainly applied to imidapril hydrochloride tablet bioequivalence, Recommanded Product: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride.

Here, the authors examined the bioequivalence of imidapril hydrochloride tablets with different amounts of imidapril hydrochloride on health adults. The results demonstrated the bioequivalence of imidapril hydrochloride tablets 2.5 mg, 5 mg and 10 mg to the reference drugs, indicating their usefulness in a clin. use.

When you point to this article, it is believed that you are also very interested in this compound(89396-94-1)Recommanded Product: (S)-3-((S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride and due to space limitations, I can only present the most important information.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

Most of the natural products isolated at present are heterocyclic compounds, so heterocyclic compounds occupy an important position in the research of organic chemistry. A compound: 89396-94-1, is researched, SMILESS is O=C([C@H](CN1C)N(C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)C1=O)O.[H]Cl, Molecular C20H28ClN3O6Journal, Systematic Reviews in Pharmacy called Comparative bioavailability study of two imidapril tablet formulations in indonesian healthy subjects, Author is Harahap, Yahdiana; Prasetyo, Vincentia; Sandra, Monika; Rahayu, Tri; Lusthom, Windy; Prasaja, Budi, the main research direction is bioavailability tablet formulation imidapril hydrochloride Indonesia.Formula: C20H28ClN3O6.

This study aimed to compare the bioavailability of two 10-mg Imidapril HCl tablet formulations using TENSIMID as the test formulation and TANAPRESS as the reference formulation. Twenty-seven healthy subjects completed a single-dosed, open-label, randomized, two-way crossover bioequivalence study under overnight fasting condition with one week wash-out period. The blood samples were collected from the subjects prior to administration and up to 12 h after dosing. Plasma concentrations of imidapril were determined using LC-MS/MS method with TurboIon Spray mode. Pharmacokinetic parameters of AUC0-t, AUC0-∞and Cmax were tested for bioequivalence after log-transformation of data and ratios of tmax was evaluated non-parametrically. The estimated points and 90% confidence interval (CI) for AUC0-t, AUC0-∞and Cmax of imidapril were 93.04% (82.63-104.76%), 93.12% (82.84-104.67%), and 94.00% (80.96-109.14%), resp. There was no statistically significant difference of tmax and t1/2 detected in both formulations (p<0.05). The result indicated that the two formulations of imidapril were bioequivalent and thus may be prescribed interchangeably. When you point to this article, it is believed that you are also very interested in this compound(89396-94-1)Formula: C20H28ClN3O6 and due to space limitations, I can only present the most important information.

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”